<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B9785FB4-7D81-4FDA-8EF6-A45A33CF55EF"><gtr:id>B9785FB4-7D81-4FDA-8EF6-A45A33CF55EF</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:surname>Kendrick</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500473"><gtr:id>80BFD693-3D8A-45DF-B2EC-8C5F389DB890</gtr:id><gtr:title>Failure of tolerance induction in the innate immune system and its contribution to clinical alcoholic hepatitis syndrome</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0500473</gtr:grantReference><gtr:abstractText>Acute alcoholic hepatitis (AAH) is a form of alcohol-related liver disease, responsible for up to 5000 deaths/year in the UK. In AAH the liver becomes rapidly inflamed leading to jaundice, bleeding, kidney failure, confusion, coma and eventually death. The best treatment is abstinence from alcohol, but once the inflammation has taken hold, many patients do not survive to reap the benefit. 

Drinking large amounts of alcohol allows toxins from the bacteria that normally live in the gut to enter the circulation and reach the liver where they stimulate the immune system, leading to inflammation. The inflammation in AAH is different from that seen in serious traumatic injury or infections where the immune system gives a sudden burst of inflammation to deal with the problem and then turns itself off to prevent damage to the body?s own tissues. In AAH the inflammation smoulders on, eventually causing liver damage. 

This study will analyse the immune system cells from the blood of patients with AAH to test the theory that alcohol itself damages the immune system and so prolongs the inflammation. Understanding this mechanism will allow the development of treatments to switch the inflammation off and allow the liver to recover.</gtr:abstractText><gtr:technicalSummary>Acute alcoholic hepatitis (AAH) is a significant health problem in the UK, accounting for up to 5000 deaths per year. Currently available treatments (over and above abstinence which, to be effective, requires the patient to survive long enough to benefit which is typically not the case) have been shown to be of little benefit, and there is a real need for increased understanding of mechanisms of disease pathogenesis and the development of new treatments. AAH is a sustained, acute inflammatory process characterised by the release of cytokines, such as TNF- and IL-6, capable of initiating hepatocyte damage. This innate immune response is considered to arise as a result of increased concentrations of lipopolysaccharide (lps), derived from gut bacteria, reaching the liver via the portal vein consequent on an ethanol-induced increase in gut permeability . There is, however, a real paradox at the heart of our understanding of the pathogenesis of AAH. In other situations where repeated exposure to lps (and other micro-organism-derived ligands which interact with the innate immune system through the toll-like receptor (TLR) family of cell surface receptors) occurs, down-regulation of the response (including levels of released cytokines) is seen. This phenomenon, conventionally known as endotoxin tolerance is thought to represent a protective, adaptive response which has evolved to prevent tissue damage resulting from un-checked cytokine release. Uniquely in AAH this down-regulation of cytokine responses fails to occur; indeed it is replaced by up-regulation with direct tissue damaging sequelae. 

This study aims to elucidate the mechanisms responsible for the failure of innate immune system tolerance in AAH by characterising the cytokine response of patient and control peripheral blood mononuclear cells to lps and other TLR ligands. If, as I hypothesise, the factor responsible for failure of tolerance is ethanol itself, the study will go on to model the immune dysregulation seen in AAH, and use this model to investigate the contribution that cellular glutathione depletion, antioxidant moieties and the different TLR signalling pathways make to the observed effect. Clarification of the dysregulatory effect of ethanol on the innate immune response and the establishment of an in vitro model will allow evaluation of potential therapeutic agents and open the way to novel treatment strategies.</gtr:technicalSummary><gtr:fund><gtr:end>2008-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>168009</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Fibrosis DPU</gtr:department><gtr:description>GSK secondment</gtr:description><gtr:id>D27E6F67-AA8C-4D99-ABDF-3C789F2B975A</gtr:id><gtr:impact>Early collaboration - no outputs yet</gtr:impact><gtr:outcomeId>WcsNoPr3cG4-1</gtr:outcomeId><gtr:partnerContribution>Drug discovery input</gtr:partnerContribution><gtr:piContribution>Academic liver medicine input</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Liver end of life group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>49292BF5-C333-4722-910A-939F94B95D12</gtr:id><gtr:impact>Produced a report on end of life care in liver disease to be published by the dept of health alongside the national liver strategy

increassing recognition of the need for specific end of life care arrangements for liver patients nationwide</gtr:impact><gtr:outcomeId>HTb74BB5aMi</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentation at regional gastroenterology meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>90DDEAB5-AC4F-4D3B-8EA5-4445CB0DEFE7</gtr:id><gtr:impact>1 hour, medical and nursing audience

support for clinical aspects of my work frommlocal professionals</gtr:impact><gtr:outcomeId>FF0EDA7DAD6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Won prize that involved presenting my work to a mixed professional/lay sudience</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>378D965D-15F4-4FD9-A620-58C6502392B2</gtr:id><gtr:impact>audience included lay trustees of medical charities

raised profile of this area of research</gtr:impact><gtr:outcomeId>57DC48A4475</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>author of textbook chapter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>7397E4D3-3C9C-4C97-BF57-EF196ED73706</gtr:id><gtr:impact>textbook for critical care specialists

publication</gtr:impact><gtr:outcomeId>829270BC4CA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCEPOD advisor</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1D5F5C27-B689-4EA1-A90F-717FA922592B</gtr:id><gtr:impact>advised on care and outcomes in national casenote review for patients who died of alcohol-related liver disease in the UK

report awaited (2013)</gtr:impact><gtr:outcomeId>mpaVoSSaELn</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>33000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European Research Advisory Board (ERAB)</gtr:department><gtr:description>European Research Advisory Board</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>25C2E7DF-2CE5-48A4-AD5F-15650DF699D8</gtr:id><gtr:outcomeId>4A966CDCB740</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>38000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Newcastle Biomedical Research Centre</gtr:department><gtr:description>Project funding</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>BH120997</gtr:fundingRef><gtr:id>E2DF2A7C-7C17-4E0D-83F1-A6A37896B94A</gtr:id><gtr:outcomeId>ttywZvLToMW</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in 5 clinical reviews</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B0421393-FA95-4131-B324-2B14EACB4150</gtr:id><gtr:impact>Increased acceptance of our findings by the international liver science community</gtr:impact><gtr:outcomeId>qEWc4aorGhe</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Potential use of theophylline in the treatment of alcoholic hepatitis - my work has demonstrated that it can improve ex vivo steroid sensitivity in this condition but it has not yet been trialled in vivo</gtr:description><gtr:id>CA2066F7-1B3E-4095-BE4B-CA331C7E1EFE</gtr:id><gtr:impact>plans for larger trial</gtr:impact><gtr:outcomeId>6F910252A5D</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>New use for existing off-patent pharmaceutical product</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Adapted existing technique to provide a constant alcohol concentration in culture media to study the effects of prolonged ethanol exposure on cells</gtr:description><gtr:id>EFAE5C3B-AE74-43EE-9736-0D77F285213D</gtr:id><gtr:impact>other groups using this method in research</gtr:impact><gtr:outcomeId>gd41JTaVWDC</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>alcohol incubator</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Modification of the human monoblastic cell line MonoMac6 - stable knockdown of acetyl-coA synthetases 1 and 2</gtr:description><gtr:id>7674C917-865A-42ED-83F6-BC3FA8389637</gtr:id><gtr:impact>paper under review</gtr:impact><gtr:outcomeId>3464FE1AAC0</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ACSS knockdown MonoMac6 line</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1F09C066-0B9A-4C54-BECE-411B8D854DCC</gtr:id><gtr:title>Theophylline improves steroid sensitivity in acute alcoholic hepatitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/006cb43e343c2c371519e7974e86b87e"><gtr:id>006cb43e343c2c371519e7974e86b87e</gtr:id><gtr:otherNames>Kendrick SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>Ararokfnvu8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CB20F4A-9C9F-4C93-94D5-6DF7A4FF9DD9</gtr:id><gtr:title>Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/006cb43e343c2c371519e7974e86b87e"><gtr:id>006cb43e343c2c371519e7974e86b87e</gtr:id><gtr:otherNames>Kendrick SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>PVrbPbiN7fv</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500473</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>